Lung cancer screening and its implications
Professor Bob Steele CBE (Dundee, UK) discusses the potential implementation of a National Screening Programme in the UK, and the view post-NELSON, as well as highlighting the next steps in… read more.
Professor Bob Steele CBE (Dundee, UK) discusses the potential implementation of a National Screening Programme in the UK, and the view post-NELSON, as well as highlighting the next steps in… read more.
The use of tyrosine kinase inhibitors (TKIs) in the treatment of ALK-positive NSCLC is now well-established. Professor Ross Camidge (University of Colorado Cancer Centre, Denver, USA) described the lessons that… read more.
Dr Popat gives an update of the ongoing studies in mesothelioma in the UK
Dr Fiona McDonald (London, UK) discusses radical treatment for oligo metastatic NSCLC and if it should be the standard of care and Professor James Spicer (London, UK), the session Chair, gives… read more.
Correvio Pharma has resubmitted a New Drug Application (NDA) to the US FDA seeking approval for Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF).
Dr Bram Verstockt (Leuven, Belgium) discusses a biopsy study looking at increases NCR+ ILC3 levels in IBD patients on biologic therapy.
IBD is still mainly a phenomenon of the Western world, but the incidence is increasing steeply in newly industrialised countries where the population is undergoing rapid urbanisation…
Metabolic interactions between the gut microbiome and its human host are thought to play a key role in the development of IBD and may hold the key to… read more.
The first-ever head-to-head comparative trial of two biological therapies in IBD indicates that UC patients treated with vedolizumab are significantly more likely to achieve remission than with adalimumab…. read more.
The sessions at ECCO 2019 were packed full of interesting data highlights and hot topics relevant to the treatment of IBD. In the video above, Professor Stefan Schreiber… read more.
As survival with frontline chemotherapy has steadily improved for patients with advanced Hodgkin lymphoma several studies have looked at how far short- and long-term toxicity can be reduced… read more.
Dr Filip Baert (Belgium) discusses the debate at UEGW on treating to target and tight monitoring in IBD.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.